Interview

Which of the currently available biomarkers come closest to the ideal biomarker?

Dr. Stacy Loeb

(28 June 2017)

 

There are better biomarkers on the market now then there were in the past. [These newer biomarker tests have a minimal risk of missing clinically significant prostate cancer.]

Blood tests such as the Prostate Health Index (PHI) and the 4Kscore are more specific for clinically significant prostate cancer than total and free PSA. The same applies to the newer urinary tests like SelectMDx that was specifically designed for assessing the risk of clinically significant prostate cancer.

We are making a lot of progress getting toward a more ideal biomarker that actually tracks significant cancer

Photo - Dr. Stacy Loeb
Dr. Stacy Loeb
New York University Langone Medical Center, New York, USA

Stay informed about new biomarker updates

Field wrapper
Country

Get a free test

Get started
* Required fields